- Johnson & Johnson's (JNJ +2%) hepatitis C drug Olysio (simeprevir) blew out Q1 expectations with its $354M in sales. Wells Fargo analyst Lawrence Biegelsen forecasted only $23M.
- Some observers believe that many physicians are prescribing the drug in combination with Gilead's (GILD +2.3%) Sovaldi (sofosbuvir) thereby inflating the full regimen cost to ~$150,000 in the U.S.
- A 12-week course of treatment of Olysio costs $66,360.
From other sites
at 4-traders.com (Mar 24, 2015)
at Nasdaq.com (Mar 16, 2015)
at Nasdaq.com (Mar 11, 2015)
at Benzinga.com (Feb 23, 2015)
at Nasdaq.com (Feb 19, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs